With Q4 sales growth of 9%, Novartis ended 2019 on a strong note. Quarterly growth predominantly came from the non-oncology portfolio. Although, Novartis’ oncology business did relatively better than Roche. Unsurprisingly, Sandoz has again lost track of growth, with Q4 impairments forcing an operating loss. Overall, Novartis’ portfolio diversity and recently unveiled focus on China render support to our investment case.
06 Feb 2020
2019 ended on a healthy note; China focus comes to the fore
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2019 ended on a healthy note; China focus comes to the fore
Novartis AG (0QLR:LON) | 0 0 0.7% | Mkt Cap: 208,186m
- Published:
06 Feb 2020 -
Author:
Surbhit Gupta -
Pages:
4
With Q4 sales growth of 9%, Novartis ended 2019 on a strong note. Quarterly growth predominantly came from the non-oncology portfolio. Although, Novartis’ oncology business did relatively better than Roche. Unsurprisingly, Sandoz has again lost track of growth, with Q4 impairments forcing an operating loss. Overall, Novartis’ portfolio diversity and recently unveiled focus on China render support to our investment case.